International Journal of Antimicrobial Agents 57 (2021) 106344

Contents lists available at ScienceDirect

International Journal of Antimicrobial Agents

journal homepage: www.elsevier.com/locate/ijantimicag

Review

Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli

Luigia Scudeller[a,1], Elda Righi[b,1,*], Margherita Chiamenti[b], Damiano Bragantini[b], Giulia Menchinelli[c,d], Paolo Cattaneo[b], Christian G. Giske[e], Thomas Lodise[f], Maurizio Sanguinetti[c,d], Laura J.V. Piddock[g], François Franceschi[g], Sally Ellis[g], Elena Carrara[b], Alessia Savoldi[b], Evelina Tacconelli[b,h,i,*]

[a] Clinical Epidemiology and Biostatistics, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano Foundation, Milan, Italy
[b] Division of Infectious Diseases, Department of Diagnostic and Public Health, University of Verona, P.Le L.A. Scuro 10, 37134 Verona, Italy
[c] Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy
[d] Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
[e] Clinical Microbiology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
[f] Albany College of Pharmacy and Health Sciences, Albany, New York, USA
[g] Global Antibiotic Research & Development Partnership (GARDP), 15 Chemin Louis-Dunant, Geneva, Switzerland
[h] Division of Infectious Diseases, Department of Internal Medicine I, German Center for Infection Research, University of Tübingen, Otfried Müller Straße 12, 72074 Tübingen, Germany
[i] German Centre for Infection Research (DZIF), Clinical Research Unit for Healthcare Associated Infections, Tübingen, Germany

ARTICLE INFO

Article history:
Received 20 January 2021
Accepted 3 April 2021

Editor: Dr Jim Gray

Keywords:
In vitro synergy
Antibiotic combination
PK/PD
Time–kill
Carbapenem-resistant bacteria

ABSTRACT

The superiority of combination therapy for carbapenem-resistant Gram-negative bacilli (CR-GNB) infections remains controversial. In vitro models may predict the efficacy of antibiotic regimens against CR-GNB. A systematic review and meta-analysis was performed including pharmacokinetic/pharmacodynamic (PK/PD) and time–kill (TK) studies examining the in vitro efficacy of antibiotic combinations against CR-GNB [PROSPERO registration no. CRD42019128104]. The primary outcome was in vitro synergy based on the effect size (ES): high, ES $\geq$ 0.75, moderate, 0.35 < ES < 0.75; low, ES $\leq$ 0.35; and absent, ES = 0). A network meta-analysis assessed the bactericidal effect and re-growth rate (secondary outcomes). An adapted version of the ToxRTool was used for risk-of-bias assessment. Over 180 combination regimens from 136 studies were included. The most frequently analysed classes were polymyxins and carbapenems. Limited data were available for ceftazidime/avibactam, ceftolozane/tazobactam and imipenem/relebactam. High or moderate synergism was shown for polymyxin/rifampicin against *Acinetobacter baumannii* [ES = 0.91, 95% confidence interval (CI) 0.44–1.00], polymyxin/fosfomycin against *Klebsiella pneumoniae* (ES = 1.00, 95% CI 0.66–1.00) and imipenem/amikacin against *Pseudomonas aeruginosa* (ES = 1.00, 95% CI 0.21–1.00). Compared with monotherapy, increased bactericidal activity and lower re-growth rates were reported for colistin/fosfomycin and polymyxin/rifampicin in *K. pneumoniae* and for imipenem/amikacin or imipenem/tobramycin against *P. aeruginosa*. High quality was documented for 65% and 53% of PK/PD and TK studies, respectively. Well-designed in vitro studies should be encouraged to guide the selection of combination therapies in clinical trials and to improve the armamentarium against carbapenem-resistant bacteria.

© 2021 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

The rapid emergence and dissemination of multidrug-resistant (MDR) Gram-negative bacilli (GNB) is recognised as a major public

* Corresponding authors. Tel.: +39 045 812 8284.
E-mail address: evelina.tacconelli@univr.it (E. Tacconelli).
[1] These two authors contributed equally to this study.

https://doi.org/10.1016/j.ijantimicag.2021.106344
0924-8579/© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

health issue [1,2]. Treatment options against carbapenem-resistant (CR) GNB remain limited [3]. To direct research and development of new antibiotics, in 2017 the World Health Organization (WHO) published a list of pathogens prioritising CR *Acinetobacter baumannii*, CR *Pseudomonas aeruginosa* and CR Enterobacteriaceae [4]. Novel compounds displaying in vitro activity against CR-GNB have been mainly tested in clinical trials, often including carbapenem-susceptible bacteria [3]. Other antibiotic classes (e.g. polymyxins, carbapenems, aminoglycosides) have been used against CR-GNB alone or in combination in observational studies [5,6]. The rationale for combining two or more antibiotics against CR-GNB is based on the possibility to achieve a higher rate of bacterial killing and to reduce the development of resistance. Despite promising results highlighted by some studies, pooled data from meta-analyses have not shown clear evidence to support the use of antibiotic combinations in the treatment of CR-GNB infections [5–8]. Moreover, results from well-designed clinical trials including infections by MDR-GNB are lacking, limiting the evidence on the effectiveness of older compared with novel compounds.

The COHERENCE project (COmbination tHErapy to treat sepsis due to carbapenem-Resistant bacteria in adult and pediatric populations: EvideNCE and common practice) aimed to coherently and comprehensively analyse data on the use of antibiotic combinations for treating severe infections caused by CR-GNB. The project was commissioned by the Global Antibiotic Research and Development Partnership (GARDP) and was intended to have a global perspective from real-world clinical practice assessment of published evidence from in vitro and clinical studies. The present article reports data deriving from the meta-analyses performed on in vitro studies.

In vitro assessments of bacterial killing and antibiotic synergism can be used to support the effectiveness of antibiotic combinations against MDR-GNB [9]. A recent meta-analysis including 26 clinical cases from 11 reports showed that synergy-guided antibiotic combination therapy against MDR-GNB (54% *P. aeruginosa*, 27% Enterobacteriaceae and 19% *A. baumannii*) was significantly associated with survival [odds ratio (OR) = 0.44, 95% confidence interval (CI) 0.20–0.98] [10].

There are currently only two meta-analyses assessing the effectiveness of antibiotic combinations against CR GNB, including in vitro studies up to March 2013 and July 2014, respectively [11,12]. These reviews, however, restricted the search only to selected pathogens and to a limited number of antibiotic dosages and combinations.

The aim of this systematic review and meta-analysis was to evaluate the in vitro activity of all available antibiotic combinations and dosages against CR (or carbapenemase-producing) strains of *A. baumannii, P. aeruginosa* and Enterobacteriaceae from time–kill (TK) and pharmacokinetic/pharmacodynamic (PK/PD) studies.

2. Methods

This review is part of the broader COHERENCE study supported by GARDP, which also includes evidence on combination therapy to treat CR-GNB infections from in vivo and human studies.

2.1. Search strategy

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13]. This systematic review is registered with the PROSPERO international prospective register of systematic reviews (www.crd.york.ac.uk/PROSPERO/; registration no. CRD42019128104).

We searched PubMed, Scopus and Web of Science databases for publications in any language from inception until 31 December 2018. All search strings were discussed with a qualified librarian. Details of the bibliographic search strategy are listed in the Supplementary methods. Bibliographies of reviews and original publications were hand-searched for further studies. To reduce publication bias, the Infectious Diseases Society of America (IDSA) and European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) conference proceedings for the years 2016–2018 were also reviewed.

2.2. Selection criteria

Reports including data of bacterial killing curves from PK/PD and TK studies analysing combination therapies against CR-GNB were included. Any type of study except reviews, editorials and protocol papers was eligible for inclusion, and all antibiotic dosage schedules and frequencies were considered. Standard inoculum sizes (4×10^5 CFU/mL or the nearest available value) were selected [14]. Gold-standard broth microdilution was considered as the susceptibility testing method.

2.3. Data extraction

Two investigators (MC and DB) independently assessed each potentially relevant study for eligibility. Disagreements were resolved by consultation with a third party (ER). If eligibility could not be determined, the full article was retrieved.

A standardised data extraction method was used to record relevant features of each study in a database, including study characteristics (year of publication, country, type of in vitro combination testing), bacterial characteristics (type of bacterial strain and number of isolated tested, method of antimicrobial susceptibility testing and carbapenemase identification) and antimicrobial therapy (type and dose of antibiotic administration, treatment duration). Bacterial isolates were considered resistant to carbapenems according to the local interpretive criteria. Unless otherwise specified, resistance was determined according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2019 breakpoints [15]. Combination therapy was defined as the association of at least two or more antibiotics used to treat CR-GNB.

Primary outcome assessed was in vitro synergy or antagonism of combination therapy defined as a >2 $\log_{10}$ reduction or increase, respectively, in CFU/mL for a combination compared with the most active single agent on bacterial kill or inhibition. Secondary outcomes included: (i) bactericidal rates, defined as a >3 $\log_{10}$ reduction in CFU/mL compared with pre-treatment counts; and (ii) regrowth rates, defined as ≥ 2 $\log_{10}$ CFU/mL decrease of the initial colony count followed by an increase of ≥ 1 $\log_{10}$ CFU/mL at two subsequent timepoints (12 h and 24 h). In TK analyses reporting multiple carbapenem doses tested within the same study, only relevant carbapenem concentrations (e.g. at least twice the resistance breakpoint for carbapenems) were included to limit heterogeneity. Studies testing single bacterial strains were excluded.

2.4. Quality assessment

An adapted version of the ToxRTool to assess in vitro studies was generated to assess the risk of bias of the included studies [16]. Details of the quality assessment are reported in the Supplementary material. In summary, studies were assigned to four categories according to their relevance and scored 0–18 points (reliable without restrictions, 15–18 points; reliable with restrictions, 11–14 points, not reliable, <11 points; not assignable, if insufficient documentation to assess the study was provided). Studies with a score of ≥ 11 points were classified as high quality.

2.5. Data analysis

We calculated each outcome separately for bacterial species, antibiotic treatment, dose and in vitro testing method. Synergy or antagonism, bactericidal rates and re-growth rates were counted as events (e.g. number of isolates showing the outcome) and the sample size was the number of isolates tested. In each study, pooled analysis of bacterial strains from the same species was performed.

For primary outcomes, pooled proportions and 95% CI of synergistic or antagonist strains were calculated in random-effect models. Due to the large number of studies showing extreme magnitude (0% and 100%) of synergy, bactericidal rates and re-growth rates, the pooled estimate was calculated after Freeman–Tukey double-arcsine transformation to stabilise the variances. CIs were based on score procedures. When applicable, the I^2 statistic was used to test heterogeneity (low, 0–0.25; fair, 0.25–0.5; moderate, 0.5–0.75; and high, >0.75). In case of high heterogeneity, the pooled effect was disregarded and not interpreted. Pooled synergy or antagonism rate was defined based on the effect size (ES) as follows: high, ES $\geq$ 0.75; moderate, 0.35 < ES < 0.75; low, ES $\leq$ 0.35; or absence of synergy, ES = 0. Positive trends were reported for synergistic combination regimens showing no significant 95% CI.

While synergy and antagonism intrinsically compare a combination therapy with its monotherapy, assessment of secondary outcomes may involve the comparison of multiple combinations with different monotherapies. For this reason, a network meta-analysis (NMA) was performed to assess bactericidal and re-growth rates [17]. Connected networks were identified for monotherapies and the corresponding combinations for bactericidal rates (proportion of strains showing bactericidal rates over the total number of strains tested) and re-growth rates (proportion of strains showing re-growth over the total number of strains tested). When applicable, inconsistency was reported. The surface under the cumulative ranking (SUCRA) curve was used for ranking different treatments [18]. Analyses were performed separately for PK/PD and TK studies. The results were clustered by study quality. Publication bias was not assessed. Stata Statistical Software: Release 16 (StataCorp LLC, College Station, TX, USA) was used for analysis.

2.6. Role of the funding source

GARDP supported the entire project, and GARDP employees contributed to study design, data interpretation and drafting the report. All authors had full access to data and had final responsibility to submit for publication.

3. Results

Our search yielded 6849 articles, including 6559 from databases, 100 from conference proceedings and 190 from bibliographies of reviews and original publications. A total of 439 full-texts were assessed and 136 studies (94 TK and 42 PK/PD) were included (Fig. 1) [19–154]. The main characteristics of all included studies and their quality assessment are presented in Supplementary Tables S1a and S1b.

3.1. Type of bacteria and antibiotic treatment

A total of 42 studies reported data on PK/PD (including 24 two-compartment and 18 one-compartment models) and 94 studies on TK; 10 studies reported data on both methods.

A total of 56 studies (43 TK and 13 PK/PD) reported data on *A. baumannii*, 54 (36 TK and 18 PK/PD) on *Klebsiella pneumoniae* and 31 (23 TK and 8 PK/PD) on *P. aeruginosa*. We also retrieved 25 studies (6 PK/PD and 19 TK) on Enterobacteriaceae other than *K. pneumoniae*. However, the data were not sufficient to perform a meta-analysis.

A total of 182 different combination regimens were tested in TK studies: 172 (95%) and 10 (5%) were double and triple combination regimens, respectively. In PK/PD studies, 21 antibiotic agents belonging to 12 classes were combined in 41 different treatments: 37 (90%) and 4 (10%) were combinations of two or three antibiotics, respectively. Table 1 summarises the most common combination regimens tested in TK and PK/PD studies. The complete list of antibiotic combinations and the type of outcome assessed for each pathogen is reported in Supplementary Table S2.

High-quality assessment was shown by 73 studies (54%) and was higher for PK/PD (65%) compared with TK (53%) studies.

3.2. Meta-analysis

Synergy rates for combination treatments were assessed by type of bacteria (e.g. *A. baumannii, K. pneumoniae* and *P. aeruginosa*) and study type (TK or PK/PD). No antagonism was detected for any treatment among the assessed studies.

3.2.1. Acinetobacter baumannii

Table 2 summarises the results for *A. baumannii.* Data from TK studies showed high synergy rates for the following combinations: meropenem and polymyxin B or colistin [ES = 0.82 (95% CI 0.23–1.00) and ES = 0.87 (95% CI 0.48–1.00), respectively], colistin and tigecycline (ES = 0.89, 95% CI 0.61–1.00) and colistin and rifampicin (ES = 0.75, 95% CI 0.41–0.99). High synergy rates were reported from single TK studies for combination of colistin and trimethoprim/sulfamethoxazole (ES = 1.00, 95% CI 0.51–1.00), polymyxin B and amikacin (ES = 1.00, 95% CI 0.34–1.00) and imipenem and tigecycline (ES = 0.80, 95% CI 0.38–0.96). PK/PD studies showed high synergy rates for colistin and rifampicin (ES = 0.91, 95% CI 0.44–1.00) and imipenem and tobramycin (ES = 1.00, 95% CI 0.38–1.00) combinations.

3.2.2. Klebsiella pneumoniae

The results for *K. pneumoniae* are reported in Table 3. TK studies showed high synergy rates for colistin and rifampicin (ES = 1.00, 95% CI 0.95–1.00) and for combination of polymyxin B and imipenem (ES = 1.00, 95% CI 0.67–1.00) or doripenem (ES = 1.00, 95% CI 0.51–1.00). High synergy rates were shown for carbapenem and aminoglycoside combination, specifically imipenem and amikacin (ES = 1.00, 95% CI 0.51–1.00) and meropenem and amikacin (ES = 1.00, 95% CI 0.51–1.00). In PK/PD studies, high synergy rates were displayed by combination of ceftazidime/avibactam and aztreonam (ES = 1.00, 95% CI 0.21–1.00) and polymyxin B and fosfomycin (ES = 1.00, 95% CI 0.66–1.00).

3.2.3. Pseudomonas aeruginosa

Table 4 summarises the results for *P. aeruginosa*. TK studies showed moderate synergy rates for combination of ceftolozane/tazobactam and colistin (ES = 0.50, 95% CI 0.15–0.85), colistin and imipenem (ES = 0.67, 95% CI 0.08–1.00) and meropenem and amikacin (ES = 0.43, 95% CI 0.31–0.55). Similar rates were shown for combination of colistin and meropenem and combination of tobramycin and imipenem. High synergy rates were shown for combination of imipenem and amikacin (ES = 1.00, 95% CI 0.21–1.00), while moderate synergy was reported for combination of colistin and doripenem in PK/PD studies.

3.3. Sensitivity analysis

Sensitivity analysis was performed on high-quality studies (defined as reliable, with or without restriction) showing ToxRTool score $\geq$11.



Fig. 1. PRISMA flow diagram of included studies.

Table 1
Most commonly analysed antibiotic combinations for time–kill (TK) and pharmacokinetic/pharmacodynamic (PK/PD) studies

Bacterium/antibiotic combination	TK study	PK/PD study	Total of studies
Acinetobacter baumannii			
Polymyxins + carbapenems	42	7	49
Polymyxins + rifampicin	20	1	21
Carbapenems + rifampicin	14	0	14
Polymyxins + tigecycline	13	2	15
Carbapenems + sulbactam	13	3	16
Total	102	13	115
Klebsiella pneumoniae			
Polymyxins + carbapenems	52	3	55
Double carbapenem	26	1	27
Polymyxins + rifampicin	17	1	18
Polymyxins + fosfomycin	6	5	11
Polymyxins + tigecycline	7	1	8
Total	108	11	119
Pseudomonas aeruginosa			
Carbapenems + aminoglycosides	25	2	27
Carbapenems + fluoroquinolones	22	1	23
Fluoroquinolones + cephalosporins	18	0	18
Polymyxins + carbapenems	8	3	11
Fluoroquinolones + aminoglycosides	10	0	10
Total	83	6	89

Table 2
In vitro synergy of antibiotic combinations against *Acinetobacter baumannii* assessed by pharmacokinetic/pharmacodynamic (PK/PD) and time–kill (TK) studies

Antibiotic regimen	Assay	No. of strains	No. of studies	No. of tests	ES	95% CI	Synergy rate
Colistin + meropenem	PK/PD	3	1	4	0.40	0.00–0.95	Positive trend
Colistin + rifampicin	PK/PD	2	1	4	0.91	0.44–1.00	High
Colistin + tigecycline	PK/PD	4	1	2	0.63	0.24–0.95	Moderate
Imipenem + tobramycin	PK/PD	1	1	3	1.00	0.38–1.00	High
Meropenem + amikacin	PK/PD	1	1	1	0.00	0.00–0.79	No synergy
Polymyxin B + tigecycline	PK/PD	4	1	2	0.08	0.00–0.43	Positive trend
Colistin + ampicillin/sulbactam	TK	2	1	1	0.00	0.00–0.66	No synergy
Colistin + ampicillin/sulbactam + rifampicin	TK	2	1	1	0.50	0.09–0.91	Moderate
Colistin + doripenem	TK	16	2	3	0.39	0.00–0.94	Positive trend
Colistin + imipenem	TK	10	2	2	0.39	0.07–0.76	Moderate
Colistin + meropenem	TK	24	3	4	0.87	0.48–1.00	High
Colistin + rifampicin	TK	24	5	7	0.75	0.41–0.99	High
Colistin + sulbactam	TK	18	1	1	0.56	0.34–0.75	Moderate
Colistin + tigecycline	TK	6	1	2	0.89	0.61–1.00	High
Colistin + trimethoprim/sulfamethoxazole	TK	4	1	1	1.00	0.51–1.00	High
Doripenem + amikacin	TK	8	1	1	0.13	0.02–0.47	Low
Doripenem + sulbactam	TK	18	1	1	0.28	0.12–0.51	Low
Imipenem + rifampicin	TK	4	2	3	0.72	0.00–1.00	Positive trend
Imipenem + tigecycline	TK	5	1	1	0.80	0.38–0.96	High
Meropenem + ampicillin/sulbactam	TK	2	1	1	0.50	0.09–0.91	Moderate
Meropenem + aztreonam	TK	5	1	1	0.00	0.00–0.43	No synergy
Polymyxin B + amikacin	TK	2	1	1	1.00	0.34–1.00	High
Polymyxin B + ampicillin/sulbactam	TK	2	1	1	0.00	0.00–0.66	No synergy
Polymyxin B + imipenem	TK	2	1	1	0.50	0.09–0.91	Moderate
Polymyxin B + meropenem	TK	4	2	2	0.82	0.23–1.00	High
Polymyxin B + meropenem + ampicillin/sulbactam	TK	2	1	1	0.50	0.09–0.91	Moderate
Polymyxin B + meropenem + rifampicin	TK	2	1	1	0.50	0.09–0.91	Moderate
Polymyxin B + rifampicin	TK	33	2	2	0.53	0.32–0.73	Moderate
Polymyxin B + tigecycline	TK	33	2	2	0.34	0.16–0.55	Low

ES, effect size; CI, confidence interval.
NOTE: Pooled synergy or antagonism rate was defined based on the ES as follows: high, ES $\geq$ 0.75; moderate, 0.35 $<$ ES $<$ 0.75; low, ES $\leq$ 0.35; and absence of synergy, ES = 0. Positive trends were reported for synergistic combination regimens showing no significant 95% CI.

Table 3
In vitro synergy of antibiotic combinations against *Klebsiella pneumoniae* assessed by pharmacokinetic/pharmacodynamic (PK/PD) and time–kill (TK) studies

Antibiotic regimen	Assay	No. of strains	No. of studies	No. of tests	ES	95% CI	Synergy rate
Ceftazidime/avibactam + amikacin	PK/PD	3	1	1	0.33	0.06–0.79	Low
Ceftazidime/avibactam + aztreonam	PK/PD	1	1	1	1.00	0.21–1.00	High
Colistin + doripenem	PK/PD	1	1	4	0.50	0.00–1.00	Positive trend
Colistin + fosfomycin	PK/PD	8	3	5	0.58	0.28–0.86	Moderate
Polymyxin B + fosfomycin	PK/PD	4	2	4	1.00	0.66–1.00	High
Meropenem + tigecycline	PK/PD	5	1	1	0.40	0.12–0.77	Moderate
Ceftazidime/avibactam + colistin	TK	16	1	1	0.25	0.10–0.49	Low
Colistin + doripenem	TK	62	5	6	0.50	0.28–0.71	Moderate
Colistin + ertapenem	TK	9	1	2	0.38	0.10–0.70	Moderate
Colistin + fosfomycin	TK	2	1	21	0.60	0.41–0.78	Moderate
Colistin + gentamicin	TK	26	2	2	0.31	0.14–0.50	Low
Colistin + meropenem	TK	9	2	2	0.12	0.00–0.46	No synergy
Colistin + meropenem + tigecycline	TK	6	1	1	0.00	0.00–0.39	No synergy
Colistin + rifampicin	TK	25	2	2	1.00	0.95–1.00	High
Colistin + tigecycline	TK	10	2	3	0.42	0.00–0.98	Positive trend
Colistin + tobramycin	TK	4	1	2	0.37	0.05–0.76	Moderate
Doripenem + ertapenem	TK	12	1	1	0.00	0.00–0.24	No synergy
Doripenem + gentamicin	TK	26	2	2	0.15	0.03–0.32	Low
Imipenem + amikacin	TK	4	1	1	1.00	0.51–1.00	High
Meropenem + amikacin	TK	4	1	1	1.00	0.51–1.00	High
Meropenem + ertapenem	TK	21	1	1	0.43	0.24–0.63	Moderate
Meropenem + gentamicin	TK	13	1	1	0.00	0.00–0.23	No synergy
Meropenem + tigecycline	TK	13	1	1	0.00	0.00–0.23	No synergy
Meropenem + tigecycline + gentamicin	TK	13	1	1	0.00	0.00–0.23	No synergy
Polymyxin B+ doripenem	TK	1	1	4	1.00	0.51–1.00	High
Polymyxin B + imipenem	TK	2	1	3	1.00	0.67–1.00	High
Polymyxin B + meropenem	TK	25	6	50	0.45	0.36–0.53	Moderate

ES, effect size; CI, confidence interval.
NOTE: Pooled synergy or antagonism rate was defined based on the ES as follows: high, ES $\geq$ 0.75; moderate, 0.35 $<$ ES $<$ 0.75; low, ES $\leq$ 0.35; and absence of synergy, ES = 0. Positive trends were reported for synergistic combination regimens showing no significant 95% CI.

Table 4
In vitro synergy of antibiotic combinations against *Pseudomonas aeruginosa* assessed by pharmacokinetic/pharmacodynamic (PK/PD) and time–kill (TK) studies

Antibiotic regimen	Assay	No. of strains	No. of studies	No. of tests	ES	95% CI	Synergy rate
Ceftazidime/avibactam + amikacin	PK/PD	3	1	1	0.33	0.06–0.79	Low
Colistin + doripenem	PK/PD	3	2	6	0.57	0.03–1.00	Moderate
Imipenem + amikacin	PK/PD	1	1	2	1.00	0.21–1.00	High
Ceftolozane/tazobactam + colistin	TK	4	1	1	0.50	0.15–0.85	Moderate
Ceftolozane/tazobactam + aztreonam	TK	4	1	1	0.00	0.00–0.49	No synergy
Ceftolozane/tazobactam + amikacin	TK	4	1	1	0.00	0.00–0.49	No synergy
Colistin + imipenem	TK	2	1	2	0.67	0.08–1.00	Moderate
Colistin + meropenem	TK	7	1	4	0.43	0.16–0.75	Moderate
Imipenem + amikacin	TK	87	4	7	0.35	0.23–0.47	Low
Imipenem + tobramycin	TK	2	1	8	0.39	0.04–0.80	Moderate
Meropenem + amikacin	TK	63	2	1	0.43	0.31–0.55	Moderate

ES, effect size; CI, confidence interval.
NOTE: Pooled synergy or antagonism rate was defined based on the ES as follows: high, ES $\geq$ 0.75; moderate, 0.35 $<$ ES $<$ 0.75; low, ES $\leq$ 0.35; and absence of synergy, ES = 0. Positive trends were reported for synergistic combination regimens showing no significant 95% CI.

3.3.1. Acinetobacter baumannii

Synergy was displayed with the combination of a polymyxin plus a carbapenem in four high-quality TK studies assessing polymyxin B/meropenem combination with or without rifampicin [39], colistin/meropenem [61], colistin/imipenem [71] and colistin/doripenem [96]. These results were not confirmed for combination of colistin and meropenem in one PK/PD study [47]. Synergy rates between 0.68 and 0.91 were confirmed for colistin and rifampicin combination both in PK/PK and TK studies [71,105,113], while colistin and polymyxin B in combination with tigecycline showed conflicting results [36,54]. High synergy rates were confirmed for imipenem plus tobramycin and colistin plus trimethoprim/sulfamethoxazole [38,89].

3.3.2. Klebsiella pneumoniae

Moderate and high synergy rates were displayed with the combination of polymyxins and fosfomycin in one TK and five PK/PD studies [21,27,28,32,40]. Polymyxin/rifampicin and polymyxin/carbapenem combinations showed, respectively, high and moderate-high synergy rates in good-quality TK studies [25,32,33,61,63,84–86,92,95,105,144,143,120].

3.3.3. Pseudomonas aeruginosa

Combination of colistin and doripenem was evaluated in two PK/PD studies [45,124]. Colistin combined with imipenem was assessed in one good-quality TK study [124]. Synergy rates were above 0.50 for both combinations. Other combinations were evaluated in good-quality PK/PD studies confirming the previous results [19,49].

3.4. Network meta-analysis

The list of antibiotic combinations tested for bactericidal activity and re-growth in PK/PD and TK studies are reported in Supplementary Table S2.

3.4.1. Acinetobacter baumannii

Data were available to perform NMAs in 10 and 19 combination regimens from PK/PD and TK studies, respectively, including polymyxin-based and doripenem-based combinations. No overall heterogeneity was identified in pairwise comparison. Significant differences in bactericidal activity between combinations and monotherapies were not shown, although in PK/PD studies a positive trend was displayed by combination of colistin and tigecycline (SUCRA = 0.8). No evidence of significant inconsistency was found. No statistically significant differences in re-growth rates were found for antibiotic combinations tested against CR *A. baumannii*.

3.4.2. Klebsiella pneumoniae

NMAs were performed to evaluate bactericidal rates in 9 and 30 combination regimens from PK/PD and TK studies, respectively. No significant heterogeneity was identified in pairwise comparison for bactericidal rates.

Significantly higher bactericidal rates were shown by polymyxin-based combinations, specifically for polymyxin B/rifampicin ($P < 0.05$) and colistin/gentamicin ($P < 0.05$) compared with a polymyxin used as monotherapy in TK studies. Carbapenem-based combinations did not show significant differences in bactericidal activity compared with monotherapy, however a higher bactericidal trend was displayed by polymyxin B plus imipenem (cumulative probability best 36.8%–SUCRA = 0.8), colistin plus ertapenem (SUCRA = 0.9) and imipenem/relebactam plus amikacin (SUCRA = 0.9). In PK/PD studies, colistin-based combinations did not present significant differences in bactericidal activity compared with colistin alone. No evidence of significant inconsistency was found. In TK studies, significant difference in re-growth rate ($P < 0.05$) was found between colistin plus fosfomycin and monotherapies at 24 h, confirmed by a lower re-growth trend at 12 h in PK/PD studies for both polymyxin B and colistin plus fosfomycin (SUCRA = 0.8). Significant differences in re-growth rates ($P < 0.05$) at 24 h were found for polymyxin B plus meropenem compared with the combination of polymyxin B plus rifampicin and for ceftazidime/avibactam compared with colistin alone in TK studies.

In TK studies, re-growth rates were significantly lower ($P < 0.05$) at 24 h for colistin and fosfomycin compared with colistin and fosfomycin used as monotherapies, for polymyxin B and meropenem compared with polymyxin B and rifampicin combination and for ceftazidime/avibactam compared with colistin monotherapy. Lower re-growth trend at 12 h was shown in PK/PD studies for both polymyxin B and colistin plus fosfomycin (SUCRA = 0.8).

3.4.3. Pseudomonas aeruginosa

Bactericidal rates were analysed for three colistin-based and three carbapenem-based combination regimens in PK/PD and TK studies, respectively.

TK studies showed that combination of meropenem and amikacin or imipenem with either amikacin or tobramycin resulted in significantly higher bactericidal effect compared with monotherapy ($P < 0.05$). In PK/PD studies, colistin-based combination with doripenem, meropenem or ceftolozane/tazobactam resulted as effective as colistin monotherapy in terms of bactericidal effect. An increased bactericidal trend was displayed by combination of colistin and ceftolozane/tazobactam (SUCRA = 0.7). No evidence of significant inconsistency was found.

Statistically significant differences ($P < 0.05$) in re-growth rates were found for combination of imipenem and amikacin or tobramycin compared with monotherapies at 24 h in TK studies. A lower re-growth trend at 24 h in PK/PD studies was shown for meropenem plus tobramycin compared with monotherapies (SUCRA = 0.9).

4. Discussion

Only two meta-analyses reporting in vitro tests assessing antibiotic combinations against CR-GNB are currently available [11,12]. Nevertheless, these studies were limited to single micro-organisms and included only certain antibiotic combinations (e.g. polymyxins plus carbapenems) with no standardisation in the selection of the antibiotic dosage used. To our knowledge, this is the first systematic review and meta-analysis of in vitro studies analysing the effect of over 180 combination therapies against three different CR-GNB.

We selected in vitro methods that are based on killing curves, specifically TK and PK/PD studies. Both methods present advantages in studying the effectiveness of combination therapies. The TK assay is one of the most used, standardised and reproducible static methods for combination testing [119,155]. PK/PD models allow the investigation of bacterial killing and re-growth simulating human drug exposure and can be considered as an accurate and informative in vitro method for studying antibiotic combination regimens [156].

Our meta-analysis showed that colistin-based and carbapenem-based combinations were the most commonly assessed regimens for all bacteria tested. This result is in line with human studies testing various combinations of old antibiotics with in vitro activity against CR-GNB, often used in association with high-dose carbapenems [3].

Few randomised controlled trials (RCTs) have investigated combination treatments against CR *A. baumannii*. One RCT comparing colistin monotherapy with colistin and rifampicin in 210 critically ill patients showed similar 30-day mortality rates (43.3% vs. 42.9%) but increased microbiological eradication among those receiving combination therapy with rifampicin compared with monotherapy (61% vs. 45%; $P = 0.034$) [157]. Similarly, a small RCT including 94 patients with CR *A. baumannii* infections assessed the combination of colistin and fosfomycin compared with colistin monotherapy, showing increased microbiological eradication but similar clinical outcomes [158]. More recently, 406 patients with severe infections caused by CR-GNB (mainly *A. baumannii*) were treated with colistin combined with meropenem, showing similar clinical failure rates compared with colistin alone (73% vs. 79%) [159]. In our study, polymyxin-based combinations with rifampicin or tigecycline resulted in high or moderate synergy against *A. baumannii* both in PK/PD and TK studies, while combination with meropenem showed high or moderate synergy rates in TK studies and was confirmed moderate in two good-quality PK/PD studies including polymyxin B. Increased bactericidal activity was displayed by combination of colistin with tigecycline or imipenem in NMA, although the differences between various combination treatments and colistin alone were not significant. Not enough data were available to investigate treatments involving fosfomycin. Overall, no studies including antibiotics approved in the last 10 years were retrieved for *A. baumannii*.

Various observational studies have analysed double or triple combination regimens against CR *K. pneumoniae*, both including old antibiotics (e.g. tigecycline, polymyxins, aminoglycosides, fosfomycin and high-dose carbapenems) and novel compounds (e.g. ceftazidime/avibactam) administered as monotherapy or as part of combination treatments [3,5,6,160]. Furthermore, few RCTs are currently ongoing comparing polymyxin/carbapenem combination with polymyxin monotherapy in CR-GNB, including CR Enterobacteriaceae [161,162].

In our study, a polymyxin combined with rifampicin or fosfomycin resulted in high or moderate synergy rates against CR *K. pneumoniae*. Association of colistin and fosfomycin, in particular, showed increased bactericidal rates in PK/PD studies and lower re-growth rate at 24 h compared with colistin or fosfomycin monotherapy.

An increased bactericidal rate was also shown for colistin/rifampicin combination compared with monotherapy. Combination of a polymyxin with a carbapenem showed high or moderate synergy rates in good-quality TK studies. Furthermore, pooled data on bactericidal activity from TK studies showed that polymyxin B combined with meropenem was associated with higher killing rates compared with polymyxin B alone and significantly lower re-growth rates at 24 h compared with polymyxin B with rifampicin. Scant data were available for novel compounds that showed in vitro activity against CR *K. pneumoniae*, such as ceftazidime/avibactam and imipenem/relebactam. Although ceftazidime/avibactam was tested in combination with various antibiotics (e.g. polymyxin B, colistin, amikacin and aztreonam), the results were retrieved mainly from single in vitro studies accounting for a limited number of strains.

Colistin, usually in association with meropenem, has been employed to treat MDR *P. aeruginosa* [163]. The use of aminoglycosides also represents a valid alternative in combination therapy, although the high risk of renal toxicity usually limits the combination of an aminoglycoside with colistin in clinical practice [164]. Our review showed that the combination of imipenem with amikacin resulted in a high synergy rate in one good-quality PK/PD study. The combination of a carbapenem with an aminoglycoside demonstrated advantages in terms of bactericidal effect and re-growth rates compared with monotherapies. In terms of bactericidal effect, however, colistin used as monotherapy showed similar results compared with other colistin-based combinations. Data on recently approved antibiotics active against CR *P. aeruginosa* were limited. Synergy for combinations including ceftazidime/avibactam and ceftolozane/tazobactam were evaluated in single studies including PK/PD and both PK/PD and TK analyses, respectively.

While our systematic review highlighted promising results for selected in vitro antibiotic combinations (including polymyxin/tigecycline and polymyxin/rifampicin against *A. baumannii*, polymyxin/fosfomycin and polymyxin/rifampicin against *K. pneumoniae*, and combination of a carbapenem with an aminoglycoside or colistin against *P. aeruginosa*), it also emphasises several drawbacks of the in vitro studies analysed. Specifically, for several combinations, definitive conclusions could not be drawn due to the limited number of reports available assessing in vitro synergism and because of the limited comparability between the available reports. Very few high-quality TK and PK/PD studies have been performed on antibiotic combinations including recently marketed antibiotics that are often used in clinical practice. Even for combinations where a meta-analysis was performed, a generalisable interpretation was hampered by a high study variability.

Our study presents several limitations. First, the high variability in bacterial strains and resistance patterns both in TK and PK/PD studies may limit the generalisability of our results. Second, as previously highlighted by others, the use of different clinical breakpoints to interpret the susceptibility profiles represents an important limitation for the analysis of efficacy of different antibiotic regimens [12]. Third, although re-growth rates were assessed at 12 h and 24 h, the emergence of resistance occurring after 24 h was not analysed since not all studies included reported these data. Finally, the overall quality of TK studies was low. For example, only 39% of TK studies specified the number of repetitions of the experiments.

Due to the propensity of CR-GNB to acquire resistance to multiple antibiotics, support from in vitro studies is important to highlight potential synergies to test in human trials. A major advantage of in vitro studies, and in particular of PK/PD models, includes the possibility to tune the bacterial inoculum and to increase the study duration in order to explore effective antimicrobial regimens. The lack of verification by clinical data, however, remains the main limitation to interpret the significance of in vitro synergies. Furthermore, a correct interpretation of in vitro results and limitations by clinicians is paramount. Results from in vitro data, however, can inform on the potential use of existing methods to explore the efficacy of antibiotic combinations and can help the optimisation of synergy tests that may be of clinical interest also at individual- and strain-specific levels.

In conclusion, we analysed over 180 antibiotic combinations against CR-GNB, most frequently involving the polymyxin and carbapenem classes. Data on combination therapy including recently approved antibiotics with activity against CR-GNB (e.g. ceftazidime/avibactam and ceftolozane/tazobactam) were limited to single studies.

For *A. baumannii*, the most consistently reported synergism was shown by colistin/rifampicin combination both from PK/PK and TK studies, while synergism between a polymyxin with either a carbapenem or tigecycline was not always shown. The association of colistin with rifampicin remains promising and has previously been demonstrated to increase the microbiological clearance of *A. baumannii* in two human RCTs, although no impact on mortality was reported [157,158]. Polymyxin/rifampicin synergism was also shown against *K. pneumoniae*, although the benefit of this combination has not been assessed in a RCT for this pathogen. Regarding *K. pneumoniae*, fosfomycin represents a potential promising option to consider, showing not only synergism but also increased bactericidal activity in association with polymyxins. Finally, the association of an aminoglycoside with imipenem showed increased synergism (e.g. imipenem and amikacin) and bactericidal activity (e.g. imipenem/amikacin or imipenem/tobramycin) against *P. aeruginosa.* Although this combination is often used in clinical practice as empirical therapy in bloodstream infections, limitations are represented by aminoglycoside nephrotoxicity and their limited lung penetration.

Our results encourage the use of high-quality in vitro studies to explore potentially promising combination regimens to be used in clinical practice and to guide the selection of therapies in future RCTs in order to improve the armamentarium against CR-GNB.

Funding: This study was funded by the Global Antibiotic Research and Development Partnership (GARDP).

Competing interests: None declared.

Ethical approval: Not required.

References

[1] Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1–12.

[2] Cassini A, Hogberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 2019;19:56–66.

[3] Peri AM, Doi Y, Potoski BA, Harris PNA, Paterson DL, Righi E. Antimicrobial treatment challenges in the era of carbapenem resistance. Diagn Microbiol Infect Dis 2019;94:413–25.

[4] Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018;18:318–27.

[5] Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing *Klebsiella pneumoniae* bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014;58:2322–8.

[6] Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: importance of combination therapy. Clin Infect Dis 2012;55:943–50.

[7] Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014;69:2305–9.

[8] Schmid A, Wolfensberger A, Nemeth J, Schreiber PW, Sax H, Kuster SP. Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: systematic review and meta-analysis. Sci Rep 2019;9:15290.

[9] Sopirala MM, Mangino JE, Gebreyes WA, et al. Synergy testing by Etest, microdilution checkerboard, and time–kill methods for pan-drug-resistant *Acinetobacter baumannii*. Antimicrob Agents Chemother 2010;54:4678–83.

[10] Vardakas KZ, Athanassaki F, Pitiriga V, Falagas ME. Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gram-negative infections: a systematic review. J Glob Antimicrob Resist 2019;17:250–9.

[11] Ni W, Shao X, Di X, Cui J, Wang R, Liu Y. In vitro synergy of polymyxins with other antibiotics for *Acinetobacter baumannii*: a systematic review and meta-analysis. Int J Antimicrob Agents 2015;45:8–18.

[12] Zusman O, Avni T, Leibovici L, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 2013;57:5104–11.

[13] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[14] *Methods for determining bactericidal activity of antimicrobial agents; approved guideline*. CLSI document M26-A. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI)CLSI; 1999.

[15] European Committee on Antimicrobial Susceptibility Testing (EUCAST). *Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019.* https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf [accessed 13 April 2021].

[16] Schneider K, Schwarz M, Burkholder I, et al. 'ToxRTool', a new tool to assess the reliability of toxicological data. Toxicol Lett 2009;189:138–44.

[17] Shim S, Yoon B-H, Shin IS, Bae JM. Network meta-analysis: application and practice using Stata. Epidemiol Health 2017;39:e2017047.

[18] Mbuagbaw L, Rochwerg B, Jaeschke R, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev 2017;6:79.

[19] Almarzoky Abuhussain SS, Kuti JL, Nicolau DP. Antibacterial activity of human simulated epithelial lining fluid concentrations of ceftazidime–avibactam alone or in combination with amikacin inhale (BAY41-6551) against carbapenem-resistant *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*. Antimicrob Agents Chemother 2018;62:e00113–18.

[20] Albur MS, Noel A, Bowker K, MacGowan A. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. Int J Antimicrob Agents 2015;46:560–7.

[21] Yu W, Zhou K, Guo L, et al. In vitro pharmacokinetics/pharmacodynamics evaluation of fosfomycin combined with amikacin or colistin against KPC2-producing *Klebsiella pneumoniae*. Front Cell Infect Microbiol 2017;7:246.

[22] Smith N, Lakota EA, Lehnard J, et al. Translating polymyxin B (PolyB) and meropenem synergy against carbapenem-resistant *Acinetobacter baumannii* (CRAB): moving toward a rational, combinatorial pharmacokinetic target 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 21–24 April 2018; Madrid, Spain ESCMID; 2018.

[23] Bergen PJ, Tsuji BT, Bulitta JB, et al. Synergistic killing of multidrug-resistant *Pseudomonas aeruginosa* at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011;55:5685–95.

[24] Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing *Klebsiella pneumoniae*. Antimicrob Agents Chemother 2011;55:3002–4.

[25] Bulman ZP, Chen L, Walsh TJ, et al. Polymyxin combinations combat *Escherichia coli* harboring *mcr-1* and bla_{NDM-5}: preparation for a postantibiotic era. mBio 2017;8 e00540-17.

[26] Bulman ZP, Satlin MJ, Chen L, et al. New polymyxin B dosing strategies to fortify old allies in the war against KPC-2-producing *Klebsiella pneumoniae*. Antimicrob Agents Chemother 2017;61:e02023–116.

[27] Zhao M, Bulman ZP, Lenhard JR, et al. Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing *Klebsiella pneumoniae*. J Antimicrob Chemother 2017;72:1985–90.

[28] Bulman ZP, Zhao M, Satlin MJ, et al. Polymyxin B and fosfomycin thwart KPC-producing *Klebsiella pneumoniae* in the hollow-fibre infection model. Int J Antimicrob Agents 2018;52:114–18.

[29] Cai Y, Lim TP, Teo JQ, et al. Evaluating polymyxin B-based combinations against carbapenem-resistant *Escherichia coli* in time–kill studies and in a hollow-fiber infection model. Antimicrob Agents Chemother 2017;61:e01509–16.

[30] Cai Y, Lim TP, Teo J, et al. In vitro activity of polymyxin B in combination with various antibiotics against extensively drug-resistant *Enterobacter cloacae* with decreased susceptibility to polymyxin B. Antimicrob Agents Chemother 2016;60:5238–46.

[31] Deris ZZ, Yu HH, Davis K, et al. The combination of colistin and doripenem is synergistic against *Klebsiella pneumoniae* at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2012;56:5103–12.

[32] Diep JK, Jacobs DM, Sharma R, et al. Polymyxin B in combination with rifampin and meropenem against polymyxin B-resistant KPC-producing *Klebsiella pneumoniae*. Antimicrob Agents Chemother 2017;61 e02121-16.

[33] Diep JK, Sharma R, Ellis-Grosse EJ, Abboud CS, Rao GG. Evaluation of activity and emergence of resistance of polymyxin B and ZTI-01 (fosfomycin

for injection) against KPC-producing *Klebsiella pneumoniae*. Antimicrob Agents Chemother 2018;62:e01815–17.
[34] Gagetti P, Pasteran F, Martinez MP, et al. Modeling meropenem treatment, alone and in combination with daptomycin, for KPC-producing *Klebsiella pneumoniae* strains with unusually low carbapenem MICs. Antimicrob Agents Chemother 2016;60:5047–50.
[35] Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against *Klebsiella pneumoniae* isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 2011;55:1420–7.
[36] Hagihara M, Housman ST, Nicolau DP, Kuti JL. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant *Acinetobacter baumannii*. Antimicrob Agents Chemother 2014;58:874–9.
[37] Housman ST, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant *Acinetobacter baumannii*. J Antimicrob Chemother 2013;68:2296–304.
[38] Landersdorfer CB, Yadav R, Rogers KE, et al. Combating carbapenem-resistant *Acinetobacter baumannii* by an optimized imipenem-plus-tobramycin dosage regimen: prospective validation via hollow-fiber infection and mathematical modeling. Antimicrob Agents Chemother 2018;62 e02053-17.
[39] Lenhard JR, Bulitta JB, Connell TD, et al. High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in *Acinetobacter baumannii*. J Antimicrob Chemother 2017;72:153–65.
[40] Wang J, He JT, Bai Y, Wang R, Cai Y. Synergistic activity of colistin/fosfomycin combination against carbapenemase-producing *Klebsiella pneumoniae* in an in vitro pharmacokinetic/pharmacodynamic model. Biomed Res Int 2018;2018:5720417.
[41] Lenhard JR, Smith NM, Bulman ZP, et al. High-dose ampicillin–sulbactam combinations combat polymyxin-resistant *Acinetobacter baumannii* in a hollow-fiber infection model. Antimicrob Agents Chemother 2017;61 e01268-16.
[42] Lenhard JR, Thamlikitkul V, Silveira FP, et al. Polymyxin-resistant, carbapenem-resistant *Acinetobacter baumannii* is eradicated by a triple combination of agents that lack individual activity. J Antimicrob Chemother 2017;72:1415–20.
[43] Lim TP, Cai Y, Hong Y, et al. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant *Klebsiella pneumoniae*. Antimicrob Agents Chemother 2015;59:2515–24.
[44] Louie A, Castanheira M, Liu W, et al. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrob Agents Chemother 2012;56:258–70.
[45] Lora-Tamayo J, Murillo O, Bergen PJ, et al. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant *Pseudomonas aeruginosa* in an in vitro dynamic biofilm model. J Antimicrob Chemother 2014;69:2434–42.
[46] Lee HJ, Bergen PJ, Bulitta JB, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant *Acinetobacter baumannii* in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013;57:3738–45.
[47] Liu X, Zhao M, Chen Y, et al. Synergistic killing by meropenem and colistin combination of carbapenem-resistant *Acinetobacter baumannii* isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model. Int J Antimicrob Agents 2016;48:559–63.
[48] Tsala M, Vourli S, Daikos G, et al. Combination therapy against multidrug resistant carbapenemase producing *Klebsiella pneumoniae* in an in vitro pharmacokinetic–pharmacodynamic model. Arch Hell Med 2018;35:198–206.
[49] McGrath BJ, Lamp KC, Rybak MJ. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against *Pseudomonas aeruginosa* in an in vitro model. Antimicrob Agents Chemother 1993;37:1931–7.
[50] MacGowan A, Tomaselli S, Noel A, Bowker K. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. J Antimicrob Chemother 2017;72:762–9.
[51] Lister PD, Wolter DJ, Wickman PA, Reisbig MD. Levofloxacin/imipenem prevents the emergence of high-level resistance among *Pseudomonas aeruginosa* strains already lacking susceptibility to one or both drugs. J Antimicrob Chemother 2006;57:999–1003.
[52] Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant *Pseudomonas aeruginosa* in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:905–9.
[53] Singh R, Kim A, Tanudra MA, et al. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother 2015;70:2618–26.
[54] Cai X, Yang Z, Dai J, et al. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant *Acinetobacter baumannii* in an in vitro pharmacodynamic model. Int J Antimicrob Agents 2017;49:609–16.
[55] Cordoba J, Coronado-Alvarez NM, Parra D, Parra-Ruiz J. In vitro activities of novel antimicrobial combinations against extensively drug-resistant *Acinetobacter baumannii*. Antimicrob Agents Chemother 2015;59:7316–19.
[56] Ghazi IM, Grupper M, Nicolau DP. Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against *Acinetobacter baumannii*. Infect Dis (Lond) 2017;49:831–9.
[57] Yadav RLC, Rogers K, Rees V, et al. Meropenem plus tobramycin combination dosage regimens against clinical hypermutable *Pseudomonas aeruginosa* at simulated epithelial lining fluid concentrations in the hollow-fibre infection model 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 21–24 April 2018; Madrid, Spain ESCMID; 2018.
[58] Beganovic ML, Daffinee K, Laplante K. Activity of minocycline, polymyxin B, sulbactam and meropenem against multidrug resistant *Acinetobacter baumannii* in a 72-hour in vitro pharmacodynamic model. 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 21–24 April 2018; Madrid, Spain ESCMID; 2018.
[59] Gomez-Junyent J, Benavent E, Sierra Y, et al. Efficacy of ceftolozane–tazobactam alone and in combination with colistin against extensively drug-resistant *Pseudomonas aeruginosa* in an in vitro pharmacodynamic biofilm model 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 21–24 April 2018; Madrid, Spain ESCMID; 2018.
[60] Lodise T, Smith NM, Holden P. Efficacy of ceftazidime–avibactam in combination with aztreonam (COMBINE): solutions for metallo-β-lactamase producing-Enterobacteriaceae (MBL). Open Forum Infect Dis 2018;5(Suppl 1):S425.
[61] Bedenic B, Beader N, Godic-Torkar K, et al. Postantibiotic effect of colistin alone and combined with vancomycin or meropenem against *Acinetobacter* spp. with well defined resistance mechanisms. J Chemother 2016;28:375–82.
[62] Huang D, Yu B, Diep JK, et al. In vitro assessment of combined polymyxin B and minocycline therapy against *Klebsiella pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae*. Antimicrob Agents Chemother 2017;61:e00073–117.
[63] Barth N, Ribeiro VB, Zavascki AP. In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials. Antimicrob Agents Chemother 2015;59:3596–7.
[64] Wilhelm CM, Nunes LS, Martins AF, Barth AL. In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant *Pseudomonas aeruginosa* isolates. Diagn Microbiol Infect Dis 2018;92:152–4.
[65] Lenhard JR, Gall JS, Bulitta JB, et al. Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant *Acinetobacter baumannii*. Int J Antimicrob Agents 2016;48:719–24.
[66] Rahim NA, Cheah SE, Johnson MD, et al. Synergistic killing of NDM-producing MDR *Klebsiella pneumoniae* by two 'old' antibiotics—polymyxin B and chloramphenicol. J Antimicrob Chemother 2015;70:2589–97.
[67] Bedenic B, Car H, Slacanac D, et al. In vitro synergy and postantibiotic effect of colistin combinations with meropenem and vancomycin against Enterobacteriaceae with multiple carbapenem resistance mechanisms. J Infect Chemother 2018;24:1016–19.
[68] Berleur M, Guerin F, Massias L, et al. Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing *Escherichia coli*. J Antimicrob Chemother 2018;73:3074–80.
[69] Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing *Klebsiella pneumoniae* in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005;56:128–32.
[70] Brennan-Krohn T, Pironti A, Kirby JE. Synergistic activity of colistin-containing combinations against colistin-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2018;62:e00873–918.
[71] Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant *Acinetobacter baumannii* isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 2007;30:537–40.
[72] Clancy CJ, Chen L, Hong JH, et al. Mutations of the *ompK36* porin gene and promoter impact responses of sequence type 258, KPC-2-producing *Klebsiella pneumoniae* strains to doripenem and doripenem–colistin. Antimicrob Agents Chemother 2013;57:5258–65.
[73] Bernabeu-Wittel M, Pichardo C, García-Curiel A, et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant *Acinetobacter baumannii* pneumonia. Clin Microbiol Infect 2005;11:319–25.
[74] Zhou YF, Tao MT, Feng Y, et al. Increased activity of colistin in combination with amikacin against *Escherichia coli* co-producing NDM-5 and MCR-1. J Antimicrob Chemother 2017;72:1723–30.
[75] Balabanian G, Rose M, Manning N, Landman D, Quale J. Effect of porins and bla_{KPC} expression on activity of imipenem with relebactam in *Klebsiella pneumoniae*: can antibiotic combinations overcome resistance? Microb Drug Resist 2018;24:877–81.
[76] Yadav R, Landersdorfer CB, Nation RL, Boyce JD, Bulitta JB. Novel approach to optimize synergistic carbapenem–aminoglycoside combinations against carbapenem-resistant *Acinetobacter baumannii*. Antimicrob Agents Chemother 2015;59:2286–98.
[77] Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant *Pseudomonas aeruginosa*. J Antimicrob Chemother 1996;38:287–91.
[78] Giamarellos Bouroulis EJ, Grecka P, Giamarellou H. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant *Pseudomonas aeruginosa*. Diagn Microbiol Infect Dis 1997;29:81–6.

[79] Song JY, Kee SY, Hwang IS, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant *Acinetobacter baumannii*. J Antimicrob Chemother 2007;60:317–22.
[80] Singkham-In U, Chatsuwan T. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant *Acinetobacter baumannii* clinical isolates. Diagn Microbiol Infect Dis 2018;91:169–74.
[81] Yadav R, Bulitta JB, Nation RL, Landersdorfer CB. Optimization of synergistic combination regimens against carbapenem- and aminoglycoside-resistant clinical *Pseudomonas aeruginosa* isolates via mechanism-based pharmacokinetic/pharmacodynamic modeling. Antimicrob Agents Chemother 2017;61:e01011–16.
[82] Gomez-Garces JL, Gil-Romero Y, Sanz-Rodriguez N, Munoz-Paraiso C, Regodon-Dominguez M. In vitro activity of fosfomycin, alone or in combination, against clinical isolates of carbapenem resistant *Pseudomonas aeruginosa* [in Spanish]. Enferm Infecc Microbiol Clin 2016;34:228–31.
[83] Shields RK, Nguyen MH, Hao B, Kline EG, Clancy CJ. Colistin does not potentiate ceftazidime–avibactam killing of carbapenem-resistant Enterobacteriaceae in vitro or suppress emergence of ceftazidime–avibactam resistance. Antimicrob Agents Chemother 2018;62:e01018.
[84] Hong JH, Clancy CJ, Cheng S, et al. Characterization of porin expression in *Klebsiella pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae* identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob Agents Chemother 2013;57:2147–53.
[85] Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing *Klebsiella pneumoniae*. Antimicrob Agents Chemother 2012;56:3395–8.
[86] Sharma R, Patel S, Abboud C, et al. Polymyxin B in combination with meropenem against carbapenemase-producing *Klebsiella pneumoniae*: pharmacodynamics and morphological changes. Int J Antimicrob Agents 2017;49:224–32.
[87] Kanellakopoulou K, Sarafis P, Galani I, Giamarellou H, Giamarellos-Bourboulis EJ. In vitro synergism of β-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of *Pseudomonas aeruginosa*. Int J Antimicrob Agents 2008;32:33–9.
[88] Rao GG, Ly NS, Diep J, et al. Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant *Acinetobacter baumannii*. Int J Antimicrob Agents 2016;48:331–6.
[89] Khalil MAF, Moawad SS, Hefzy EM. In vivo activity of co-trimoxazole combined with colistin against *Acinetobacter baumannii* producing OXA-23 in a *Galleria mellonella* model. J Med Microbiol 2019;68:52–9.
[90] Rao GG, Ly NS, Bulitta JB, et al. Polymyxin B in combination with doripenem against heteroresistant *Acinetobacter baumannii*: pharmacodynamics of new dosing strategies. J Antimicrob Chemother 2016;71:3148–56.
[91] Queenan AM, Davies TA, He W, Lynch AS. Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible *Acinetobacter baumannii* isolates from nosocomial pneumonia patients. J Chemother 2013;25:141–7.
[92] Kulengowski B, Campion JJ, Feola DJ, Burgess DS. Effect of the meropenem MIC on the killing activity of meropenem and polymyxin B in combination against KPC-producing *Klebsiella pneumoniae*. J Antibiot (Tokyo) 2017;70:974–8.
[93] Kulengowski B, Clark JA, Burgess DS. Staggering the administration of polymyxin B and meropenem in time–kill against carbapenem-resistant Enterobacteriaceae exhibiting a wide range of meropenem MICs. Diagn Microbiol Infect Dis 2019;93:261–4.
[94] Poirel L, Kieffer N, Nordmann P. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 2016;71:156–61.
[95] Pachon-Ibanez ME, Labrador-Herrera G, Cebrero-Cangueiro T, et al. Efficacy of colistin and its combination with rifampin in vitro and in experimental models of infection caused by carbapenemase-producing clinical isolates of *Klebsiella pneumoniae*. Front Microbiol 2018;9:912.
[96] Principe L, Capone A, Mazzarelli A, et al. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant *Acinetobacter baumannii*: possible options for the treatment of complicated infection. Microb Drug Resist 2013;19:407–14.
[97] Oleksiuk LM, Nguyen MH, Press EG, et al. In vitro responses of *Acinetobacter baumannii* to two- and three-drug combinations following exposure to colistin and doripenem. Antimicrob Agents Chemother 2014;58:1195–9.
[98] Ozbek B, Mataraci-Kara E, Er S, Ozdamar M, Yilmaz M. In vitro activities of colistin, tigecycline and tobramycin, alone or in combination, against carbapenem-resistant Enterobacteriaceae strains. J Glob Antimicrob Resist 2015;3:278–82.
[99] Kulengowski B, Rutter WC, Campion JJ, Lee GC, Feola DJ, Burgess DS. Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing *Enterobacter cloacae*. Diagn Microbiol Infect Dis 2018;92:262–6.
[100] Lai CC, Chen CC, Huang HL, Chuang YC, Tang HJ. The role of doxycycline in the therapy of multidrug-resistant *E. coli*—an in vitro study. Sci Rep 2016;6:31964.
[101] Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant *Acinetobacter baumannii* in a mouse pneumonia model. J Antimicrob Chemother 2004;54:1085–91.
[102] Laishram S, Anandan S, Devi BY, et al. Determination of synergy between sulbactam, meropenem and colistin in carbapenem-resistant *Klebsiella pneumoniae* and *Acinetobacter baumannii* isolates and correlation with the molecular mechanism of resistance. J Chemother 2015;28:297–303.
[103] Lim TP, Tan TY, Lee W, et al. In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant *Acinetobacter baumannii* in Singapore. PLoS One 2011;6:e18485.
[104] Le J, McKee B, Srisupha-Olarn W, Burgess DS. In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing *Klebsiella pneumoniae*. J Clin Med Res 2011;3:106–10.
[105] Lee GC, Burgess DS. Polymyxins and doripenem combination against KPC-producing *Klebsiella pneumoniae*. J Clin Med Res 2013;5:97–100.
[106] Teo J, Lim TP, Hsu LY, Tan TY, Sasikala S, Hon PY, et al. Extensively drug-resistant *Acinetobacter baumannii* in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal polymyxin B-based combinations. Antimicrob Resist Infect Control 2015;4:2.
[107] Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant *Acinetobacter baumannii*. Antimicrob Agents Chemother 2004;48:753–7.
[108] Su J, Li D, Guo Q, Guo Y, Zheng Y, Xu X. In vitro bactericidal activity of trimethoprim–sulfamethoxazole/colistin combination against carbapenem-resistant *Klebsiella pneumoniae* clinical isolates. Microb Drug Resist 2018;25:152–6.
[109] Yim H, Woo H, Song W, Park MJ, Kim HS, Lee KM, et al. Time–kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant *Klebsiella pneumoniae* and *Escherichia coli*. Ann Clin Lab Sci 2011;41:39–43.
[110] Yang YS, Lee Y, Tseng KC, et al. In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant *Acinetobacter baumannii*. Antimicrob Agents Chemother 2016;60:4047–54.
[111] Tascini C, Gemignani G, Ferranti S, et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant *Pseudomonas aeruginosa* infections. J Chemother 2004;16:282–7.
[112] Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 2009;53:2360–6.
[113] Pachon-Ibanez ME, Docobo-Perez F, Lopez-Rojas R, et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant *Acinetobacter baumannii*. Antimicrob Agents Chemother 2010;54:1165–72.
[114] Leite GC, Oliveira MS, Perdigao-Neto LV, et al. Antimicrobial combinations against pan-resistant *Acinetobacter baumannii* isolates with different resistance mechanisms. PLoS One 2016;11:e0151270.
[115] Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Antimicrob Agents Chemother 2008;52:333–6.
[116] Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant *Pseudomonas aeruginosa*. J Chemother 2003;15:235–8.
[117] Ozbek B, Otuk G. In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant *Acinetobacter baumannii* strains isolated from intensive care units. Int J Antimicrob Agents 2010;36:191–2.
[118] Pankuch GA, Seifert H, Appelbaum PC. Activity of doripenem with and without levofloxacin, amikacin, and colistin against *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Diagn Microbiol Infect Dis 2010;67:191–7.
[119] Peck KR, Kim MJ, Choi JY, et al. In vitro time–kill studies of antimicrobial agents against blood isolates of imipenem-resistant *Acinetobacter baumannii*, including colistin- or tigecycline-resistant isolates. J Med Microbiol 2012;61:353–60.
[120] Mezzatesta ML, Caio C, Gona F, Zingali T, Salerno I, Stefani S. Colistin increases the cidal activity of antibiotic combinations against multidrug-resistant *Klebsiella pneumoniae*: an in vitro model comparing multiple combination bactericidal testing at one peak serum concentration and time–kill method. Microb Drug Resist 2016;22:360–3.
[121] Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant *Acinetobacter baumannii*. Ann Clin Microbiol Antimicrob 2009;8:18.
[122] Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J. Activities of colistin- and minocycline-based combinations against extensive drug resistant *Acinetobacter baumannii* isolates from intensive care unit patients. BMC Infect Dis 2011;11:109.
[123] Sader HS, Rhomberg PR, Jones RN. In vitro activity of β-lactam antimicrobial agents in combination with aztreonam tested against metallo-β-lactamase-producing *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. J Chemother 2005;17:622–7.
[124] Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL, et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant *Pseudomonas aeruginosa* at multiple inocula. Antimicrob Agents Chemother 2011;55:5134–42.
[125] Sopirala MM, Mangino JE, Gebreyes WA, et al. Synergy testing by Etest, mi-

crodilution checkerboard, and time–kill methods for pan-drug-resistant *Acinetobacter baumannii*. Antimicrob Agents Chemother 2010;54:4678–83.
[126] Cirioni O, Ghiselli R, Silvestri C, et al. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant *Pseudomonas aeruginosa* strain. Antimicrob Agents Chemother 2007;51:2005–10.
[127] Choi JY, Soo Park Y, Cho CH, et al. Synergic in-vitro activity of imipenem and sulbactam against *Acinetobacter baumannii*. Clin Microbiol Infect 2004;10:1098–101.
[128] Visalli MA, Jacobs MR, Appelbaum PC. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of *Pseudomonas aeruginosa* by checkerboard and time–kill methodology. Antimicrob Agents Chemother 1998;42:953–5.
[129] Yang H, Chen G, Hu L, Liu Y, et al. In vivo activity of daptomycin/colistin combination therapy in a *Galleria mellonella* model of *Acinetobacter baumannii* infection. Int J Antimicrob Agents 2015;45:188–9.
[130] Sun Y, Wang L, Li J, et al. Synergistic efficacy of meropenem and rifampicin in a murine model of sepsis caused by multidrug-resistant *Acinetobacter baumannii*. Eur J Pharmacol 2014;729:116–22.
[131] Roussel-Delvallez M, Wallet F, Delpierre F, Courcol RJ. In vitro bactericidal effect of a β-lactam + aminoglycoside combination against multiresistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. J Chemother 1996;8:365–8.
[132] Rao GG, Ly NS, Soon RL, Roman S, Kelchlin PA, Holden PN. Polymyxin B in combination with doripenem against *Acinetobacter baumannii* demonstrates high synergy and suppression of resistance. In: Proceedings of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 9–12 September 2012; San Francisco, CA. Washington, DC. ASM Press; 2012.
[133] Moland ES, Craft DW, Hong SG, et al. In vitro activity of tigecycline against multidrug-resistant *Acinetobacter baumannii* and selection of tigecycline–amikacin synergy. Antimicrob Agents Chemother 2008;52:2940–2.
[134] Mutlu Yilmaz E, Sunbul M, Aksoy A, Yilmaz H, Guney AK, Guvenc T. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant *Acinetobacter baumannii*. Int J Antimicrob Agents 2012;40:332–6.
[135] Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against *Pseudomonas aeruginosa*. Diagn Microbiol Infect Dis 2003;46:131–7.
[136] Safarika A, Galani I, Pistiki A, Giamarellos-Bourboulis EJ. Time–kill effect of levofloxacin on multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: synergism with imipenem and colistin. Eur J Clin Microbiol Infect Dis 2015;34:317–23.
[137] Martin L, Pares AS, Plasencia V, et al. Colistin plus azithromycin as an alternative treatment of infections caused by multidrug resistant *Pseudomonas aeruginosa* 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 22–25 April 2017; Vienna, Austria ESCMID; 2017.
[138] Bedenić B, Beader N, Francula-Zaninovic S, et al. In vitro synergy and postantibiotic effect of colistin combined with meropenem against Enterobacteriaceae with multiple carbapenem-resistance mechanisms 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 22–25 April 2017; Vienna, Austria ESCMID; 2017.
[139] Teo J, Lim TP, Tan SX, et al. Evaluation of polymyxin B (PB)-based and dual–carbapenem combinations against carbapenem resistant Enterobacteriaceae co-harbouring *mcr-1* and KPC-2. In: 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2017.
[140] Pachon-Ibanez ME, Docobo-Perez F, Jimenez-Mejias ME, et al. Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant *Acinetobacter baumannii* strains. Eur J Clin Microbiol Infect Dis 2011;30:895–901.
[141] Giamarellos-Bourboulis EJ, Kentepozidis N, Antonopoulou A, Plachouras D, Tsaganos T, Giamarellou H. Postantibiotic effect of antimicrobial combinations on multidrug-resistant *Pseudomonas aeruginosa*. Diagn Microbiol Infect Dis 2005;51:113–17.
[142] Phee LM, Betts JW, Bharathan B, Wareham DW. Colistin and fusidic acid, a novel potent synergistic combination for treatment of multidrug-resistant *Acinetobacter baumannii* infections. Antimicrob Agents Chemother 2015;59:4544–50.
[143] Del Bono V, Giacobbe DR, Marchese A, et al. Meropenem for treating KPC-producing *Klebsiella pneumoniae* bloodstream infections: should we get to the PK/PD root of the paradox? Virulence 2017;8:66–73.
[144] Clancy CJ, Hao B, Shields RK, et al. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing *Klebsiella pneumoniae* strains with various *ompK36* genotypes. Antimicrob Agents Chemother 2014;58:3521–5.
[145] Liu B, Bai Y, Liu Y, et al. In vitro activity of tigecycline in combination with cefoperazone–sulbactam against multidrug-resistant *Acinetobacter baumannii*. J Chemother 2015;27:271–6.
[146] Zhang W, Guo Y, Li J, et al. In vitro and in vivo bactericidal activity of ceftazidime–avibactam against carbapenemase-producing *Klebsiella pneumoniae*. Antimicrob Resist Infect Control 2018;7:142.
[147] Chopra S, Matsuyama K, Tran T, Madrid P. Systematic discovery of synergistic novel antibiotic combinations targeting multidrug-resistant *Acinetobacter baumannii*. Int J Antimicrob Agents 2012;40:377–9.
[148] Drago L, De Vecchi E, Nicola L, Colombo A, Guerra A, Gismondo MR. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin–tazobactam and amikacin against different *Pseudomonas aeruginosa* phenotypes and *Acinetobacter* spp. Chemotherapy 2004;50:202–10.
[149] Mataraci-Kara E, Yilmaz M, Ozbek Çelik B. In vitro effectiveness of cefepime alone or in combination with sulbactam against OXA-48 positive carbapenem-resistant *Klebsiella pneumoniae* isolates. 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 21–24 April 2018; Madrid, Spain ESCMID; 2018.
[150] Montero M, Ochoa SD, Lopez Causape C, et al. In vitro synergistic effects of colistin plus meropenem combination on extensively drug-resistant (XDR) *Pseudomonas aeruginosa* high-risk clones 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 21–24 April 2018; Madrid, Spain ESCMID; 2018.
[151] Borjan J, Meyer KA, Wenzler E. Synergistic activity of ceftazidime–avibactam in combination with polymyxin B against carbapenem-resistant *Klebsiella pneumoniae*. IDWeek 3–7 October 2018; San Francisco, CA; 2018.
[152] Monogue M, Nicolau DP. In vitro antibacterial activity of ceftolozane/tazobactam (C/T) alone and in combination with other antimicrobial agents against multidrug-resistant (MDR) *Pseudomonas aeruginosa* (PSA). IDWeek 4–8 October 2017; San Diego, CA; 2017.
[153] Netto B, Vieira BJ, Hermes DM, Ribeiro VB, Zavascki AP. In vitro activity of non-bactericidal concentrations of polymyxin B in combination with other antimicrobials against OXA-23-producing carbapenem-resistant *Acinetobacter baumannii*. Braz J Infect Dis 2013;17:502–4.
[154] Nivedita S, Nguyen L, Ryback MJ, Kaye KS. Evaluation of meropenem (MEM) in combination with colistin (COL) against colistin resistant extensively drug resistant (XRD) Gram negative bacteria. Open Forum Infect Dis 2018;5(Supp 1):S727.
[155] Tängdén T, Hickman RA, Forsberg P, Lagerbäck P, Giske CG, Cars O. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing *Klebsiella pneumoniae* by in vitro time–kill experiments. Antimicrob Agents Chemother 2014;58:1757–62.
[156] Rao GG, Li J, Garonzik SM, Nation RL, Forrest A. Assessment and modelling of antibacterial combination regimens. Clin Microbiol Infect 2018;24:689–96.
[157] Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant *Acinetobacter baumannii*: a multicenter, randomized clinical trial. Clin Infect Dis 2013;57:349–58.
[158] Sirijatuphat R, Thamlikitkul V. Colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant *Acinetobacter baumannii* infections: a preliminary study. Antimicrob Agents Chemother 2014;58:5598–601.
[159] Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 2018;18:391–400.
[160] Onorato L, Di Caprio G, Signoriello S, Coppola N. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis. Int J Antimicrob Agents 2019;54:735–40.
[161] ClinicalTrials.gov. Polymyxin B monotherapy vs combination therapy in critically ill patients with multi-drug resistant pathogens. NCT03159078. https://clinicaltrials.gov/ct2/results?cond=&term=NCT03159078&cntry=&state=&city=&dist= [accessed 13 April 2021].
[162] ClinicalTrials.gov. Trial for the treatment of extensively drug-resistant Gram-negative bacilli. NCT01597973. https://clinicaltrials.gov/ct2/results?cond=&term=NCT01597973&cntry=&state=&city=&dist= [accessed 13 April 2021].
[163] Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant *Pseudomonas aeruginosa*. Clin Infect Dis 2003;37:154–60.
[164] Falagas ME, Rafailidis PI, Kasiakou SK, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin–meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006;12:1227–30.